Information Provided By: 
Fly News Breaks for January 7, 2019
AMAG
Jan 7, 2019 | 10:32 EDT
Piper Jaffray analyst Christopher Raymond maintained a Neutral rating and $20 price target on AMAG Pharmaceuticals after the company pre-released below-consensus Q4 results and initial FY19 guidance that broadly brackets consensus expectations. The analyst also has concerns about Vyleesi, which has a pushed out PDUFA date of June 23, 2019, and Makena, as there is another generic now on the market, and recommends staying on the sidelines.
News For AMAG From the Last 2 Days
There are no results for your query AMAG
